Reaction Biology, one of the industry’s leading providers of drug discovery services, today announced that twelve abstracts highlighting data from the company’s oncology drug discovery services platform will be presented at the 2022 Annual Meeting of the American Association for Cancer Research (AACR), which will be held April 8-13. , 2022, in New Orleans, Louisiana.

Image Credit: afotostock/Shutterstock.com

“At AACR 2022, we look forward to showcasing data from our comprehensive suite of innovative drug discovery services that continue to support our customers in their oncology research goals,said Haiching Ma, Ph.D., Scientific Director of Reaction Biology.With this data, we continue to build our capabilities as a global leader and partner in drug discovery.”

New data will be presented on the Company’s diacylglycerol kinase assay panel, which will help researchers better inform the discovery of isoform-specific inhibitors and provide researchers with ten new lipid targets for the first time. kinase. Additionally, Reaction will share data on a novel biological approach, leading to improved preclinical characterization of adavosertib, a WEE-1 inhibitor.

Reaction will present data from a number of new and improved tests and other oncology drug discovery services. The full range of data presented at the AACR includes:

• Development of diacylglycerol kinase assays to facilitate the discovery of isoform-specific inhibitors (Sunday, April 10, 2022, 1:30 p.m. – 5:00 p.m.; poster section 8, Billboard number: 24, Permanent abstract number: 170)
• Characterization of KRas pathway inhibitors in 2D and 3D screening formats (Sunday, April 10, 2022, 1:30 p.m. – 5:00 p.m.; poster section 23, Billboard number: 7, Permanent abstract number: 357)
• Application of NanoBRET Target Engagement Cellular Assay for Measurement of Inhibitor Binding to Wild-Type and Mutant RAS in Live Cells (Sunday 10 April 2022, 1.30 p.m. – 5 p.m.; Poster Section 24, Billboard number: 15, Permanent abstract number: 379)
• Benefits of Using a Flow Spectral Analyzer for Analysis of Immune Cell Populations in Tumors (Sunday, April 10, 2022, 1:30 p.m. – 5:00 p.m.; Poster Section 39, Billboard number: 14, Permanent abstract number: 629)
• A systems biology approach combining ProLiFiler and Cancer Data Miner for better preclinical characterization of adavosertib, a WEE-1 inhibitor (Monday 11 April 2022, 9:00 – 12:30; Section 24 Poster, Billboard number: 22, Permanent abstract number: 1132)
• Comparison and consequences of different implantation techniques on the orthotopic growth of Hepa1-6 syngeneic liver cancer cells (Monday, April 11, 2022, 1:30 p.m. – 5:00 p.m.; Poster Section 11, Billboard number: 13, Permanent abstract number: 1621)
• Probing PRMT5 Inhibitors with Distinct Binding Modes Using Surface Plasmon Resonance (Tuesday 12 April 2022, 9:00 – 12:30; Section 40 Poster, Billboard number: 6, Permanent abstract number: 2921)
• Exploring the combinatorial potential of bispecific T-cell engagers in a high-throughput format (Tuesday 12 April 2022, 9:00 – 12:30; Section 38 Poster, Billboard number: 8, Permanent abstract number: 2893)
• Comprehensive characterization of CDK inhibitors using a full panel of all 20 human cyclin-dependent kinases (Tuesday 12 April 2022, 9:00 – 12:30; Section 5 of the poster, billboard number: 8, permanent summary number: 2304)
• Real-time quantitative PCR-based analysis of transcriptional effects of CDK8/Cyclin C inhibitors (Tuesday April 12, 2022, 9 a.m. – 12:30 p.m.; Poster Section 5, Billboard number: 22, Permanent abstract number: 2318)
• A versatile assay suite for the discovery of novel KRAS pathway inhibitors (Tuesday 12 April 2022, 1.30 p.m. – 5 p.m.; Poster Section 4, Billboard number: 16, Permanent abstract number: 2987)
• Cytotoxic effects of LRRK2 inhibitors in combination treatment with chemotherapeutic agents on a large panel of cancer cell lines (Wednesday, April 13, 2022, 9:00 a.m. – 12:30 p.m.; Section 27 Poster, Billboard number: 26, Permanent abstract number: 4072)

“This year, we celebrate the company’s 20-year history of delivering superior science and driving customer-centric innovation, while building on our growing range of services and support. complete,said John H. Johnson, President and CEO and Director of Reaction Biology.

This data at AACR represents the breadth and depth of Reaction Biology’s preclinical research services in oncology and underscores why we are a preferred global partner in drug discovery.

John H. Johnson, President and CEO and Director of Reaction Biology

Copies of the poster presentations will be available at Reaction Biology’s booth (#1247) during exhibit hall hours April 10-13 and on the company’s website.